Cyclopharm's USA Technegas Expansion Update
| Stock | Cyclopharm Ltd (CYC.ASX) |
|---|---|
| Release Time | 20 Dec 2024, 11:06 a.m. |
| Price Sensitive | Yes |
Cyclopharm's USA Technegas Expansion Update
- 17 Technegas installations at leading US healthcare institutions
- Technegas delivers superior image quality and broad clinical applications
- Technegas provides operational efficiency and low radiation exposure
Cyclopharm Limited (ASX: CYC) is pleased to provide an update on its expanding presence in the United States healthcare market following the successful clinical deployment of its Technegas technology at several prestigious medical institutions. Since receiving US FDA approval and full reimbursement by the Center for Medicare and Medicaid, Cyclopharm is seeing an increase in customer conversion for Technegas. The company now has 17 Technegas installations operational across leading clinical sites in the US, including Barnes-Jewish Hospital, Emory University Hospitals, Boston Medical Center, and Massachusetts General Hospital, among others. The clinical implementation of Technegas at these institutions reinforces its global reputation as a trusted and effective tool for functional lung imaging. Technegas offers unparalleled advantages, including superior image quality, broad clinical applications beyond pulmonary embolism, operational efficiency, and low radiation exposure. Cyclopharm's market expansion in the US, along with increasing the use of Technegas for new indications, are cornerstones of the company's strategy to deliver sustainable growth and shareholder value. The successful implementation of Technegas at these leading healthcare institutions highlights its operational and clinical benefits, as well as the significant market opportunity for its adoption across a broader range of respiratory conditions.
Cyclopharm is seeing an increase in customer conversion for Technegas, with 17 installations now operational at leading US healthcare institutions. This is driving revenue growth for the company.
Cyclopharm is focused on continuing to expand its footprint in the US market and driving long-term value for its shareholders through the adoption of Technegas for a broader range of respiratory conditions.